July 4 – 13:30 – 14:30 CEST
The purpose of this seminar is to provide a comprehensive overview of radionuclide therapy using alpha-emitting isotopes, focusing on their current clinical and preclinical applications. It will explore the unique advantages of alpha emitters, such as their high linear energy transfer and short path length, which allow for precise tumor cell killing with minimal damage to surrounding tissue. The seminar will also address key challenges, including limited availability of suitable alpha-emitting radionuclides, complex radiochemistry, and safety concerns during production and handling. Emphasis will be placed on production routes, chelation strategies, and conjugation chemistry that enable targeted delivery to cancer cells. Finally, the session will critically evaluate the therapeutic potential and limitations of alpha therapy, highlighting areas for future research and clinical translation.


